Navigation Links
KBI Biopharma Selects Freeslate’s Biologics Formulation System for Early and Late Stage Drug Development
Date:9/3/2013

SUNNYVALE, Calif. (PRWEB) September 03, 2013

Freeslate, Inc., the leading provider of high throughput research solutions, today announced that KBI Biopharma, Inc. (KBI), a leading development and contract manufacturing organization serving the biopharmaceutical industry, has purchased Freeslate’s Biologics Formulation System to help develop more robust formulations using less time and material. The Biologics Formulation System is based on Freeslate’s Core Module 3 (CM3) automation platform and provides a new, high throughput research approach to address challenges in biologics formulation.

“The KBI team is excited to begin using Freeslate’s Biologics Formulation System to support our biologics formulation screening during early-stage development, as well as formulation robustness studies and process optimization during later stage development”, said Joseph McMahon, President and CEO for KBI. “We selected Freeslate’s technology because the system was designed for biologics formulation, combining key capabilities that can be used across both early and late stage development projects allowing us to screen a broader range of conditions and reduce product consumption while accelerating our clients’ development timelines.”

“At Freeslate, we are dedicated to advancing biologics formulation with integrated, automated solutions that address the complex problems of drug development,” said John S. Senaldi, President and CEO of Freeslate. “We have built strong capabilities in this area and are pleased to partner with KBI to continue those advances and support the important research they are doing on behalf of their clients.”

Freeslate’s Biologics Formulation System supports the entire formulation development process through the combination of automated sample prep and new high throughput capabilities for pH measurement, viscosity measurement, and visual inspection/particle counting. The system also integrates with critical analytics like Dynamic Light Scattering, High Pressure Liquid Chromatography, and UV/VIS plate readers. It enables users to develop more candidates, with more robust formulations, in a shorter period of time, with less material, with no increase in personnel. By both generating and managing data from orthogonal analytics, the system helps drive informed decision making.

KBI will serve as a reference site for Freeslate, hosting customers, product demonstrations, and participating in speaking engagements and seminars to help educate others on the available high throughput research tools. The two companies will also collaborate on future product development.

About Freeslate

Freeslate is a privately held company that provides products and related services for high throughput research. Based on its proprietary laboratory automation platforms, high throughput pressure reactors, and integrated Lab Execution and Analysis (LEA) software suite, the company enables dramatic gains in its customers’ productivity and innovation by delivering seamlessly integrated automation solutions. Freeslate leverages its scientific expertise through its team of Ph.D. scientists, engineers, and software developers with directly relevant experience in the industries it serves. Collaborating with customers for more than a decade, the business has provided high throughput research solutions for the pharmaceutical, chemical, and energy industries. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit http://www.freeslate.com.

About KBI

KBI Biopharma, Inc. is a leading development and contract manufacturing organization serving the biopharmaceutical industry. KBI helps client partners accelerate and optimize drug development and manufacturing programs by offering an extensive suite of expert development and manufacturing services in an agile, client-friendly partnering environment. Clients include global pharmaceutical and biotechnology companies and academic/non-profit organizations. Today, KBI serves more than 150 customers in the US, Canada, Europe, Korea and Japan, including most of the top ten pharmaceutical companies. KBI was founded in 1996 and is based in Durham, North Carolina, near Research Triangle Park (RTP).

KBI’s extensive track record of successful process development and manufacturing programs is a result of its unique approach of applying the insight gained from our biophysical and biochemical protein characterization methodologies, towards the development of robust and scalable processes. KBI delivers expert and integrated process development and cGMP manufacturing of recombinant protein Active Pharmaceutical Ingredients (API) for its clients. For more information, please visit http://www.kbibiopharma.com.

Media Contact:
Mikelle Thatcher
Marketing Communications Specialist
Freeslate, Inc.
Direct: 408-773-4081
Email: mikelle(dot)thatcher(at)freeslate(dot)com

KBI Biopharma Technical Inquiries:
Tim Kelly, Ph.D.
VP Biopharmaceutical Development
KBI Biopharma, Inc.
Phone: (919) 479-9898 ext 2045
Email: tkelly(at)kbibiopharma(dot)com

Read the full story at http://www.prweb.com/releases/2013/9/prweb11080598.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
3. CeNeRx BioPharma Completes $4.85 Million Financing
4. PDL BioPharma Completes Regular Quarterly Dividend Payment
5. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
6. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
7. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
8. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
9. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
10. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
11. Laureate Biopharma Appoints Les Mintzmyer, Vice President, Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... 20, 2017 , ... CNSDose is a genetically driven, clinically ... by finding the right antidepressant faster. CNSDose speeds recovery and reduces side ... personalized approach to treatment. , A peer-reviewed and published, 12-week double-blind ...
(Date:5/18/2017)... Mass. (PRWEB) , ... May 18, 2017 , ... ... the procedure on April 28, 2017 at the Prince Of Wales Private Hospital. ... cervical disc at level C6-C7. The patient failed conservative treatments prior to undergoing ...
(Date:5/18/2017)... , ... May 17, 2017 , ... NDA Partners Chairman ... and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit ... his position at Eurofins and Cardinal Health, he was former Chief Operating Officer at ...
(Date:5/18/2017)... ... May 17, 2017 , ... USDM ... firm for the life sciences and healthcare industries, is honored that Jay ... Medical Devices conference in Brussels, Belgium. , Crowley played a crucial role in ...
Breaking Biology Technology:
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
Breaking Biology News(10 mins):